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Abstract  
We report on a 76-year-old male patient who developed a maculopapular generalised exanthema due to 
terbinafine. Prick test was negative; patch test revealed a positive reaction after 48 h confirming the delayed-type 
allergic reaction. Non-pustular exanthema has only rarely been reported for terbinafine. 
 
. 
 
 
 
 
 
 
 
 
 
A 76-year-old male patient presented to our 
department for Allergology diagnostic. He reported 
about an itchy dermatosis that developed the year 
before. He suffered for many years from 
onychomycosis and recurrent tinea pedum. In May 
2016 he was treated for the first time by systemic 
terbinafine because of tinea pedum. About four weeks 
later he developed of a generalised maculopapular 
exanthema. Terbinafine therapy was stopped. The 
exanthema completely disappeared within two weeks 
by oral prednisolone in tapering-down doses. 
The medical history was negative for atopic 
diseases and known allergies, but he suffered from a 
mild depression treated with clomipramine. No other 
medical drugs were used by our patient.  
On examination, we observed a photo skin 
type II according to Fitzpatrick, tinea pedum, but no 
urticarial dermographism. 
We performed patch test and pricked test with 
terbinafine. After 20 in, prick test remained negative. 
Positive control with 0.1% histamine showed an 
urticarial response of 3 mm to 30 mm with some 
pseudopodia.  
Patch test revealed a positive reaction to the 
offending drug with multiple papules and erythema 
(++) after 48 h (Fig. 1). 
Terbinafine is a frequently used allylamine 
antimycotic drug that inhibits squalene epoxidase and 
thereby ergosterols biosynthesis of fungi [1]. Adverse 
reactions have been documented with an incidence of 
2.7% [2]. The most common findings are acute 
generalised pustulosis, urticaria, gastrointestinal 
symptoms, taste loss, and liver toxicity [2-5].  
An uncommon adverse effect is the 
development of drug-induced lupus erythematosus, 
mostly of the subacute-cutaneous subtype [6], and 
induction or exacerbation of psoriasis [7]. 
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Figure 1: Positive patch test reaction with terbinafine after 48 h  
 
In contrast, to pustular exanthema non-
pustular erythema has rarely been described. George 
et al. (2015) observed a case of pityriasis rosea-like 
eruption due to terbinafine. Zheng et al. (2017) 
described a lichenoid drug eruption by terbinafine two 
weeks after initiation of treatment. Maculo-papular 
exanthema due to terbinafine has not been described, 
although it might be underrepresented in the medical 
literature. 
We could confirm the allergic reaction to 
terbinafine. Although a generalised exanthema had 
been observed, we identified a type-IV reaction not a 
type-I reaction to terbinafine. Maculo-papular 
exanthema and systemic drug-related intertriginous 
and flexural exanthema (SDRIFE) are the most 
common symptoms of a delayed drug reaction [8, 9]. 
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